• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Zynex Announces Partnership To Conduct Business with Veterans Affairs (VA) Medical Centers, the Largest Healthcare Network in the United States

    12/17/24 9:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ZYXI alert in real time by email

    VA Spending on Hospital and Medical Care Exceeds $112 Billion Annually

    ENGLEWOOD, Colo., Dec. 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced a new partnership to conduct business with Veterans Affairs Medical Centers (VAMCs) across the United States. This collaboration reflects Zynex's commitment to improving access to high-quality care for our nation's veterans.

    Zynex

    It is estimated that the VA spends over $112 billion annually on healthcare. This partnership enables Zynex to bring its advanced pain management solutions to a critical and growing market, with the VA's system alone servicing over 9 million enrolled veterans. Currently, less than 1% of Zynex's sales are from VAMCs and the partnership provides an opportunity to significantly expand sales into the largest healthcare network in the U.S.

    With 171 VAMCs and over 1,100 outpatient facilities nationwide, the Department of Veterans Affairs serves millions of veterans annually. Additionally, there are approximately 700 Military Treatment Facilities (MTFs) operated by the Department of Defense, forming an extensive network for addressing the healthcare needs of service members and their families.

    "Our partnership to do business with the VA represents a significant milestone in expanding access to non-opioid pain management solutions for those who have served our country," said Thomas Sandgaard, CEO, Founder, and Chairman. "Working with the VA provides us with access to the largest healthcare network in the United States and we are honored to help enhance the quality of care for veterans nationwide."

    As part of this collaboration, Zynex's sales team will work closely with healthcare providers within the VA and MTF networks to deliver its full product suite of innovative, pain management treatments designed to improve patient outcomes while addressing the unique pain management needs of these populations.

    About Zynex, Inc.

    Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

    Safe Harbor Statement

    This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

    Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2023 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.

    Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    Investor Relations Contact:

    Brian Prenoveau, CFA

    MZ Group – MZ North America

    [email protected]

    +561 489 5315

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-announces-partnership-to-conduct-business-with-veterans-affairs-va-medical-centers-the-largest-healthcare-network-in-the-united-states-302333802.html

    SOURCE Zynex, Inc.

    Get the next $ZYXI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZYXI

    DatePrice TargetRatingAnalyst
    3/12/2025$11.00 → $5.50Outperform → Sector Perform
    RBC Capital Mkts
    3/12/2025Buy → Neutral
    Ladenburg Thalmann
    10/16/2023$13.00Outperform
    RBC Capital Mkts
    1/6/2023$10.00 → $18.00Neutral → Overweight
    Piper Sandler
    2/28/2022$15.50 → $10.00Buy
    B. Riley Securities
    2/25/2022$22.00 → $20.00Buy
    HC Wainwright & Co.
    7/30/2021$25.00 → $22.00Buy
    HC Wainwright & Co.
    7/16/2021$19.50Neutral → Buy
    B. Riley Securities
    More analyst ratings

    $ZYXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Disbrow Joshua R. was granted 10,000 shares, increasing direct ownership by 80% to 22,500 units (SEC Form 4)

      4 - ZYNEX INC (0000846475) (Issuer)

      5/16/25 6:00:09 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Cress Michael D was granted 10,000 shares, increasing direct ownership by 80% to 22,500 units (SEC Form 4)

      4 - ZYNEX INC (0000846475) (Issuer)

      5/16/25 6:00:05 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Michaels Barry D was granted 10,000 shares, increasing direct ownership by 80% to 22,500 units (SEC Form 4)

      4 - ZYNEX INC (0000846475) (Issuer)

      5/16/25 6:00:08 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zynex downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Zynex from Outperform to Sector Perform and set a new price target of $5.50 from $11.00 previously

      3/12/25 7:36:55 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded Zynex from Buy to Neutral

      3/12/25 7:36:29 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • RBC Capital Mkts initiated coverage on Zynex with a new price target

      RBC Capital Mkts initiated coverage of Zynex with a rating of Outperform and set a new price target of $13.00

      10/16/23 7:17:56 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Zynex Inc. (Amendment)

      SC 13D/A - ZYNEX INC (0000846475) (Subject)

      5/24/23 6:26:30 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    Leadership Updates

    Live Leadership Updates

    See more
    • Zynex Announces Open Oximetry Project Membership

      ENGLEWOOD, Colo., Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its membership in the Collaborative Community of the independently led Open Oximetry Project as an industry member. The Open Oximetry Project, an initiative led by the University of California, San Francisco's Center for Health Equity in Surgery and Anesthesia, is dedicated to i

      12/3/24 9:15:00 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Announces Change of Auditor

      ENGLEWOOD, Colo., June 13, 2022 /PRNewswire/ -- Zynex, Inc. ("Zynex or the "Company) (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has changed its auditors from Plante & Moran, PLLC ("Plante Moran") as the Company's independent registered accounting firm to Marcum LLP effective June 13, 2022. The appointment of Marcum LLP was made after careful consideration and an evaluation process by the Company and approved by the Board of Directors and the Audit Committee of the Company.

      6/13/22 4:30:00 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Appoints Donald Gregg as Vice President of Sales and Operations of Monitoring Solutions Division

      ENGLEWOOD, Colo., April 20, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has hired Donald Gregg as the Vice President of Sales and Operations of its Monitoring Solutions Division. In this position, Donald will lead operations, sales, marketing and product development of the Monitoring Solution Division including the production and launch of the CM-1500 Blood Volume Monitor which was granted 510(k) clearance by the U.S. Food and Drug Administration in 2020.

      4/20/21 9:15:00 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zynex Submits FDA Application for Its NiCO Laser Pulse Oximeter

      ENGLEWOOD, Colo., May 12, 2025 /PRNewswire/ --  Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration ("FDA") for its NiCO™, Noninvasive CO-Oximeter device. This submission marks a historic milestone in the evolution of pulse oximetry and a major breakthrough for the Company in its mission to improve the quality of care and patient outco

      5/12/25 9:15:00 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Reports First Quarter 2025 Financial Results

      ENGLEWOOD, Colo., April 29, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. Management Commentary  "In the first quarter of 2025, we continued to see steady orders for our pain management and private-labeled rehabilitation products. Total orders decreased 3% year-over-year, but our sales force headcount was ap

      4/29/25 4:02:00 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Sets First Quarter 2025 Earnings Call

      ENGLEWOOD, Colo., April 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, April 29, 2025 at 4:15 PM Eastern Time to discuss its financial results for the first quarter ended March 31, 2025.  Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Tuesday

      4/22/25 9:15:00 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    Financials

    Live finance-specific insights

    See more
    • Zynex Reports First Quarter 2025 Financial Results

      ENGLEWOOD, Colo., April 29, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. Management Commentary  "In the first quarter of 2025, we continued to see steady orders for our pain management and private-labeled rehabilitation products. Total orders decreased 3% year-over-year, but our sales force headcount was ap

      4/29/25 4:02:00 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Sets First Quarter 2025 Earnings Call

      ENGLEWOOD, Colo., April 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, April 29, 2025 at 4:15 PM Eastern Time to discuss its financial results for the first quarter ended March 31, 2025.  Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Tuesday

      4/22/25 9:15:00 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Reports Fourth Quarter and Full Year 2024 Financial Results

      ENGLEWOOD, Colo., March 11, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024. Key Highlights and Business Update FY 2024 orders increased 16% year-over-yearFY 2024 net revenue increased 4% to $192.4 millionFY 2024 net income of $3.0 million; Diluted EPS $0.09FY 2024 cash flow from operations of

      3/11/25 4:08:00 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    SEC Filings

    See more
    • Zynex Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ZYNEX INC (0000846475) (Filer)

      5/15/25 5:11:13 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ZYNEX INC (0000846475) (Filer)

      5/14/25 5:04:50 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Zynex Inc.

      10-Q - ZYNEX INC (0000846475) (Filer)

      4/29/25 5:00:23 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Disbrow Joshua R. bought $58,233 worth of shares (7,000 units at $8.32), increasing direct ownership by 11% to 72,000 units (SEC Form 4)

      4 - ZYNEX INC (0000846475) (Issuer)

      7/30/24 6:25:26 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care